Coya Therapeutics, Inc. (COYA) Stock

Coya Therapeutics, Inc. (COYA) is a Healthcare stock trading at $4.92 (as of 2026-06-18), with a market capitalization of $113.06M and a trailing P/E of -4.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing medicinal product candidates designed to modulate regulatory T-cell (Treg) function. Its pipeline includes COYA 101 for amyotrophic lateral sclerosis, additional Treg-focused biologics and exosome-based therapies for neurodegenerative and autoimmune indications, and related candidates in IND-enabling, preclinical, or discovery stages.

Valuation — source: SEC EDGAR (first-party)
Price	$4.92
Market Cap	$113.06M
P/E Ratio	-4.1
EV / EBITDA	-2.7
Price / Book	2.27
Price / Sales	14.01
DCF Value (model)	$-5.80
DCF Upside vs Price	-217.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$7.95M
Net Margin	-267.1%
Return on Equity	-43.1%
Current Ratio	15.02
Revenue Growth (YoY)	123.6%
EPS Growth (YoY)	29.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	7.99 (safe)

Valuation vs Sector & Industry
Stock P/E	-4.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-119.7%
vs Industry	-124.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	GREENLIGHT CAPITAL INC ($9.44M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Arun Swaminathan
Employees	8
Country	US
IPO Date	2022-12-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.